ASHG 2026 has ended. This guide stays up as the record of who was there. Next: ASHG 2027, Oct 26–30, 2027 in Nashville

Helix at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Helix brings 9 presentations to ASHG 2026 in Montréal, and exhibits at Booth 1200. Its program centres on population-scale genomic screening, clinical genetics, and therapeutic research using clinico-genomic data. Its presentations cover three-year outcomes of screening 527,000 participants for CDC Tier 1 conditions, rare GLP1R variants affecting semaglutide weight loss, and pharmacogenomic testing that reverses excess clopidogrel hospitalizations.

OrganizationASHG 2026 Attendance
Helix
San Mateo, California
2 Senior Research Scientist · 1 Medical Director · 1 Associate Director Research · 1 Senior Staff Scientist
Private company
Helix sells population-scale genomic testing, clinico-genomic data, and research tools to health systems and life-science companies.
Helix signed a multi-year deal giving AstraZeneca access to its growing, deeply phenotyped GenoSphere cohorts for drug discovery research.
›
Helix signed a multi-year deal giving AstraZeneca access to its growing, deeply phenotyped GenoSphere cohorts for drug discovery research.
2026-07 · source
Helix launched a GenoSphere MCP connector inside Claude Science, making its genomic data directly accessible through AI tools.
2026-07 · source
Nebraska Medicine and Memorial Hermann launched Helix Genomic Advantage, a new population health system partnership improving care and lowering cost.
2026-06 · source
Source: company newsroom
Raised $50M Series C (Jun 2021)
›
Led by Warburg Pincus, DFJ Growth, Kleiner Perkins, Mayo Clinic, and Temasek; most recent disclosed round. · 2021-06-03
“The $50M round will be used to accelerate the organization's population genomics platform.”
Source: funding announcement
Booth
Exhibiting at Booth 1200
Wed, Oct 219:30am–4:30pmThu, Oct 229:30am–6:15pmFri, Oct 239:30am–4:30pm
Plenary
Tue Oct 20
5:57 pm
CDCT1 Screening in 527K Participants: A 3-year Outcomes Study
Collaborators: Memorial Hermann, Parkview Health +10 more
Genetic testingPopulation geneticsClinical geneticsPrecision medicine
Poster
Thu Oct 22
4:15 pm
APOE genotype shapes the trajectory from mild cognitive impairment to dementia in a large clinical genomics cohort
NeurodegenerationElectronic health recordsGenotype-phenotype correlationsPrecision medicine
Poster
Thu Oct 22
4:15 pm
ApoB isoform-specific mechanisms of liver disease in heterozygous pLoF carriers across three population cohorts
Collaborators: University of Nevada, Reno
Clinical geneticsGenetic variationLarge-scale biobanks
Poster
Fri Oct 23
2:30 pm
Poster
Fri Oct 23
2:30 pm
Plasma proteomic signatures of kidney disease within APOL1 genotype strata in a population genomic screening program
Clinical testingGenetic testingMetabolic disorderPrecision medicine
Poster
Fri Oct 23
2:30 pm
Poster
Fri Oct 23
2:30 pm
Cumulative pharmacogenomic variant burden associates with polypharmacy, treatment inefficacy, and adverse drug events
Collaborators: St. Luke's University Health Network
PharmacogenomicsPharmacologic therapyGenetic variationGenotype-phenotype correlations

Explore the full ASHG 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Montréal. Leave your work email and we’ll be in touch.

Privacy

Download the full ASHG 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Helix

Tell us what you sell and we’ll find the people at Helix most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction